226 related articles for article (PubMed ID: 26918292)
1. Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics.
Albertsson-Wikland K; Mårtensson A; Sävendahl L; Niklasson A; Bang P; Dahlgren J; Gustafsson J; Kriström B; Norgren S; Pehrsson NG; Odén A
J Clin Endocrinol Metab; 2016 May; 101(5):2149-59. PubMed ID: 26918292
[TBL] [Abstract][Full Text] [Related]
2. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.
Sävendahl L; Maes M; Albertsson-Wikland K; Borgström B; Carel JC; Henrard S; Speybroeck N; Thomas M; Zandwijken G; Hokken-Koelega A
J Clin Endocrinol Metab; 2012 Feb; 97(2):E213-7. PubMed ID: 22238393
[TBL] [Abstract][Full Text] [Related]
3. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.
Carel JC; Ecosse E; Landier F; Meguellati-Hakkas D; Kaguelidou F; Rey G; Coste J
J Clin Endocrinol Metab; 2012 Feb; 97(2):416-25. PubMed ID: 22238382
[TBL] [Abstract][Full Text] [Related]
4. Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study.
Quigley CA; Child CJ; Zimmermann AG; Rosenfeld RG; Robison LL; Blum WF
J Clin Endocrinol Metab; 2017 Sep; 102(9):3195-3205. PubMed ID: 28575299
[TBL] [Abstract][Full Text] [Related]
5. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
Ross JL; Lee PA; Gut R; Germak J
Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
[TBL] [Abstract][Full Text] [Related]
6. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of recombinant human growth hormone in children.
Bell J; Parker KL; Swinford RD; Hoffman AR; Maneatis T; Lippe B
J Clin Endocrinol Metab; 2010 Jan; 95(1):167-77. PubMed ID: 19906787
[TBL] [Abstract][Full Text] [Related]
8. Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity.
Tidblad A; Bottai M; Kieler H; Albertsson-Wikland K; Sävendahl L
JAMA Pediatr; 2021 Feb; 175(2):e205199. PubMed ID: 33346824
[TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy in children: The use of growth hormone and IGF-I.
Pfäffle R
Best Pract Res Clin Endocrinol Metab; 2015 Jun; 29(3):339-52. PubMed ID: 26051295
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of children born small for gestational age with short stature who qualify for growth hormone treatment.
Tamaro G; Pizzul M; Gaeta G; Servello R; Trevisan M; Böhm P; Materassi PMA; Macaluso A; Valentini D; Pellegrin MC; Barbi E; Tornese G
Ital J Pediatr; 2021 Apr; 47(1):82. PubMed ID: 33794966
[TBL] [Abstract][Full Text] [Related]
11. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994.
Root AW; Kemp SF; Rundle AC; Dana K; Attie KM
J Pediatr Endocrinol Metab; 1998; 11(3):403-12. PubMed ID: 11517956
[TBL] [Abstract][Full Text] [Related]
12. [State of health of populations residing in geothermal areas of Tuscany].
Minichilli F; Nuvolone D; Bustaffa E; Cipriani F; Vigotti MA; Bianchi F
Epidemiol Prev; 2012; 36(5 Suppl 1):1-104. PubMed ID: 23139155
[TBL] [Abstract][Full Text] [Related]
13. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review.
Ranke MB; Lindberg A
Horm Res Paediatr; 2011; 75(6):423-32. PubMed ID: 21358173
[TBL] [Abstract][Full Text] [Related]
14. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
15. Growth response and metabolic effects of growth hormone therapy in appropriate-for-gestational-age growth hormonedeficient children in relation to birth size and gestational age: A preliminary study.
Witkowska-Sędek E; Stelmaszczyk-Emmel A; Kucharska A; Rumińska M; Majcher A; Pyrżak B
Acta Biochim Pol; 2020 Nov; 67(4):509-514. PubMed ID: 33242242
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Final Height in Patients Born Small for Gestational Age Treated with Recombinant Growth Hormone.
Adler E; Lambert AS; Bouvattier C; Thomas-Teinturier C; Rothenbuhler A; de Boissieu P; Linglart A
Horm Res Paediatr; 2021; 94(1-2):52-62. PubMed ID: 34182561
[TBL] [Abstract][Full Text] [Related]
17. Near adult heights after growth hormone treatment in patients with idiopathic short stature or idiopathic growth hormone deficiency.
Frindik JP; Kemp SF; Hunold JJ
J Pediatr Endocrinol Metab; 2003 May; 16 Suppl 3():607-12. PubMed ID: 12795361
[TBL] [Abstract][Full Text] [Related]
18. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
Hughes IP; Harris M; Choong CS; Ambler G; Cutfield W; Hofman P; Cowell CT; Werther G; Cotterill A; Davies PS;
Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731
[TBL] [Abstract][Full Text] [Related]
20. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
